Luis
Supply Chain at Apellis
Apellis and Sobi: The New England Journal of Medicine Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan to Eculizumab for PNH
Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy
Apellis Provides Update on APL-9 for Severe COVID-19
are targeted C3 therapies. These include potential medicines for a broad range of serious diseases driven by uncontrolled or excessive activation of the complement system.
CLINICAL TRIALSWe challenge conventional thinking and always question if there's a better way.
Join UsPatricia
Quality Assurance at Apellis